AIM ImmunoTech Inc
Veridion Score
Composite trend over time
Why is AIM moving today?
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for AIM.
AIM insider activity
AIM ImmunoTech Inc
No multi-insider buying cluster in the last 90 days
Net buying: $1.3M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-10 | 2026-03-06 | Equels Thomas K | Insider | buy | $25,000 | 25 | 25 | $625K | SEC Form 4 |
| 2026-03-10 | 2026-03-06 | CHEMEROW DAVID I. | Insider | buy | $25,000 | 25 | 25 | $625K | SEC Form 4 |
| 2026-02-06 | 2026-02-05 | CHEMEROW DAVID I. | Insider | buy | $1.23 | 2,800 | 3,441 | $3K | SEC Form 4 |
AIM contract awards, year to date.
Public federal awards linked to this ticker.
AIM lobbying filings, year to date.
Registered lobbying filings matched to AIM ImmunoTech Inc.